New research sits at the center of this dementia and brain health question.
A cheap, decades-old anti-seizure medication called levetiracetam may fundamentally change how we prevent Alzheimer’s disease. Published in February 2026 in *Science Translational Medicine*, a study from Northwestern University found that levetiracetam — sold under the brand name Keppra and available as a generic for a fraction of the cost of newer therapies — prevents neurons from forming amyloid-beta 42, one of the most toxic proteins linked to Alzheimer’s. Analysis of patient records from the National Alzheimer’s Coordinating Center showed that Alzheimer’s patients who took levetiracetam lived significantly longer after the onset of cognitive decline — by several years on average — compared to patients on other anti-seizure drugs or no medication at all.
The headline figure of “30 percent risk reduction” that has been circulating does not come from one single study. It appears to be a rough average drawn from several recent breakthroughs: lecanemab (brand name Leqembi) slowed cognitive decline by 27 percent in its Phase 3 trial, while Eli Lilly’s donanemab showed a 35 percent slowing of clinical decline and a 39 percent lower risk of progressing to the next stage of disease. What makes the levetiracetam finding different — and arguably more exciting — is that this is a drug millions of people already take safely, it costs pennies compared to antibody infusions, and it works by stopping amyloid plaques from forming in the first place rather than clearing them after the damage is underway. This article breaks down what the Northwestern research actually found, how it compares to the newer antibody treatments like lecanemab and donanemab, what the limitations are, and what all of this means for families navigating dementia risk right now.
Table of Contents
- What Does the New Research Say About a Common Drug Reducing Alzheimer’s Risk?
- How Levetiracetam Compares to Newer Alzheimer’s Antibody Treatments
- The Washington University Prevention Trial and What It Means for Early Intervention
- What High-Risk Individuals Should Know About Prevention Options Right Now
- Why the “30 Percent” Headline Deserves Careful Scrutiny
- The Cost and Access Problem That Could Limit These Breakthroughs
- What Comes Next in Alzheimer’s Prevention Research
- Conclusion
- Frequently Asked Questions
What Does the New Research Say About a Common Drug Reducing Alzheimer’s Risk?
The Northwestern study, led by researchers at Feinberg School of Medicine, discovered the specific mechanism by which levetiracetam interferes with Alzheimer’s pathology. The drug binds to a protein called SV2A during the synaptic vesicle cycle — the process by which brain cells communicate with one another. By attaching to SV2A, levetiracetam prevents neurons from producing amyloid-beta 42, the particular fragment of amyloid protein most associated with the toxic plaques that accumulate in Alzheimer’s brains. This is not a case of a drug modestly reducing symptoms. The research suggests levetiracetam could stop a central part of the disease process before it even begins. The clinical evidence backing this up comes from a correlative analysis, not a randomized controlled trial. Researchers examined records from thousands of Alzheimer’s patients through the National Alzheimer’s Coordinating Center and compared outcomes between those who happened to be on levetiracetam (typically prescribed for epilepsy or seizures) and those on other anti-seizure medications or none at all.
The levetiracetam group showed a meaningfully longer period between the onset of cognitive decline and death. To put that in concrete terms: if two patients both begin showing memory problems at age 72, the one taking levetiracetam might live to 80 while the other might live to 76 or 77. Those extra years matter enormously to families. The critical caveat is timing. The researchers noted that to be most effective, high-risk individuals would likely need to begin taking levetiracetam up to 20 years before cognitive decline becomes detectable. That means a person with strong genetic risk factors might need to start the drug in their 40s or 50s — long before any symptoms appear. This raises difficult questions about screening, long-term medication use in healthy people, and how to identify who would benefit most.
How Levetiracetam Compares to Newer Alzheimer’s Antibody Treatments
Lecanemab and donanemab represent the other major front in Alzheimer’s treatment, and they work on a fundamentally different principle. Both are monoclonal antibodies designed to clear amyloid plaques that have already formed in the brain. Lecanemab received FDA accelerated approval and showed a 27 percent slowing of cognitive decline in its 18-month Phase 3 trial. Donanemab, developed by Eli Lilly under the brand name Kisunla, went further — participants experienced a 39 percent lower risk of progressing to the next stage of disease and a 35 percent slowing of both clinical and functional decline. These are real, measurable benefits for people already in early stages of Alzheimer’s. However, the antibody treatments come with significant trade-offs that levetiracetam does not share. Lecanemab and donanemab require regular intravenous infusions at specialized clinics, carry a risk of brain swelling and microbleeds (known as ARIA), and cost tens of thousands of dollars per year.
Levetiracetam, by contrast, is an oral pill taken at home, has a well-established safety profile from decades of use in epilepsy patients, and costs a small fraction of the antibody therapies. For a family already stretched thin by caregiving costs, the difference between a $200-per-year generic pill and a $26,000-per-year infusion regimen is not trivial. The limitation here is that these treatments are not directly comparable. Lecanemab and donanemab are designed for people who already have early-stage Alzheimer’s — they are interventions for active disease. Levetiracetam’s promise, based on the Northwestern findings, is primarily as a preventive measure for people who have not yet developed symptoms. If a clinical trial confirms that levetiracetam can prevent or delay Alzheimer’s onset in high-risk individuals, it would fill a completely different role in the treatment landscape than the antibody drugs. The two approaches might ultimately be complementary rather than competing.
The Washington University Prevention Trial and What It Means for Early Intervention
One of the most striking recent findings in Alzheimer’s prevention comes from a trial conducted at Washington University in St. Louis. Researchers studied 73 people who carry rare inherited genetic mutations that cause their brains to overproduce amyloid protein, virtually guaranteeing they will develop Alzheimer’s at a young age. After participants took an anti-amyloid drug for an average of eight years, the risk of developing symptoms dropped from nearly 100 percent to approximately 50 percent. That is a roughly 50 percent risk reduction in a population that was otherwise certain to develop the disease. this trial matters because it provides the strongest evidence to date that intervening early — years or even decades before symptoms appear — can meaningfully change whether a person develops Alzheimer’s at all. The participants were not people with vague risk factors.
They were genetically destined to get the disease, and half of them did not, because they started treatment early enough. For families dealing with early-onset Alzheimer’s driven by these rare mutations, this is closer to a breakthrough than anything the field has produced in decades. The obvious limitation is scale. The study involved only 73 people with extremely rare genetic profiles. Whether these results translate to the far more common sporadic form of Alzheimer’s — the kind that affects the vast majority of patients — remains an open question. But the principle it demonstrates aligns with what the Northwestern levetiracetam study suggests: the earlier you intervene in the amyloid cascade, the better your chances. The challenge is figuring out who needs early intervention and how to deliver it affordably and safely across millions of people.
What High-Risk Individuals Should Know About Prevention Options Right Now
If you have a parent or sibling with Alzheimer’s, or if you carry the APOE4 gene variant, the natural question is whether you should ask your doctor about levetiracetam today. The honest answer is that it is too early. The Northwestern findings are based on correlative data from patient records, not a prospective clinical trial where one group took levetiracetam and another took a placebo. Correlation does not prove causation — it is possible that something else about the patients who happened to be on levetiracetam contributed to their better outcomes. A controlled trial is the necessary next step, and those take years to design, fund, and complete. That said, levetiracetam’s established safety profile makes it a more realistic candidate for a prevention trial than most drugs.
It has been prescribed to millions of epilepsy patients worldwide, its side effects are well-documented and generally manageable, and it is already FDA-approved. The barrier to testing it as an Alzheimer’s preventive is not safety concerns but rather the logistical challenge of running a trial that would need to follow healthy participants for 10 to 20 years to see whether they develop Alzheimer’s at lower rates than a control group. In the meantime, the actionable steps for high-risk individuals have not changed. Regular cardiovascular exercise, management of blood pressure and diabetes, cognitive engagement, quality sleep, and social connection remain the most evidence-supported modifiable risk factors for Alzheimer’s. These are not as dramatic as a pill that stops amyloid production, but they are available right now, they are free, and they carry no pharmaceutical side effects. The levetiracetam research gives reason for genuine optimism about the future, but it does not replace the fundamentals of brain health today.
Why the “30 Percent” Headline Deserves Careful Scrutiny
The claim that a common drug reduces Alzheimer’s risk by 30 percent is a composite figure, and that distinction matters. No single study published to date has reported exactly a 30 percent risk reduction from one drug in a broad Alzheimer’s population. Lecanemab showed a 27 percent slowing of cognitive decline. Donanemab showed 35 percent slowing and 39 percent reduced risk of progression. The levetiracetam study found a multi-year delay in disease progression but did not report a specific percentage of risk reduction. The “30 percent” is a headline-friendly number that roughly splits the difference, and while it is not wrong in spirit, it obscures important differences between the drugs and the studies.
This matters because Alzheimer’s research has a painful history of overpromising and underdelivering. For decades, families have read headlines about imminent breakthroughs only to see the drugs fail in later trials or produce side effects that outweighed their benefits. The current generation of research is genuinely more promising than what came before — lecanemab and donanemab are the first drugs to show statistically significant slowing of decline in rigorous Phase 3 trials, and levetiracetam’s mechanism of action is well understood. But precision in how we talk about these results is not pedantry. It is respect for the families who are making decisions about care and hope based on what they read. Anyone evaluating these findings should ask three questions: What was the study population? Was this a controlled trial or a correlative analysis? And does “reducing risk” mean preventing the disease entirely, slowing its progression, or delaying the onset of symptoms? These are different outcomes with different implications for patients, and conflating them in a headline does a disservice to the real progress being made.
The Cost and Access Problem That Could Limit These Breakthroughs
Even if every drug mentioned in this article works exactly as hoped, access will remain a serious barrier. Lecanemab costs approximately $26,500 per year and requires biweekly intravenous infusions at a medical facility equipped to handle potential side effects like brain swelling. Donanemab carries similar costs and administration requirements. Medicare coverage for these drugs has been contentious, with shifting policies that leave many patients uncertain about whether they will be able to afford treatment.
For families already bearing the financial burden of Alzheimer’s caregiving — which the Alzheimer’s Association estimates at over $300 billion annually in the United States — adding a five-figure annual drug cost is not a small ask. This is precisely why the levetiracetam finding has generated so much excitement outside of academic circles. If a drug that costs a few hundred dollars a year and can be taken as a pill at home turns out to prevent or significantly delay Alzheimer’s, it would be one of the most cost-effective medical interventions in history. The gap between a treatment that works and a treatment that people can actually access is one of the defining challenges in Alzheimer’s care, and levetiracetam — if the science holds up — could bridge it.
What Comes Next in Alzheimer’s Prevention Research
The next two to three years will be pivotal. The Northwestern levetiracetam findings will almost certainly prompt calls for a large-scale, prospective clinical trial — the kind of study that can establish causation rather than just correlation. Designing such a trial will be complicated by the long timeline involved; if the drug needs to be started 20 years before symptoms appear, researchers will need to either follow participants for decades or find biomarker-based endpoints that can confirm the drug is working long before cognitive decline shows up on standard tests. Advances in blood-based biomarkers for amyloid and tau may make this feasible in a way it was not even five years ago.
Meanwhile, the antibody drugs will continue generating real-world data as more patients begin treatment. Longer-term follow-up from the lecanemab and donanemab trials will clarify whether the benefits seen at 18 months persist, grow, or plateau over several years. And the Washington University prevention trial opens the door to studying whether anti-amyloid treatment can prevent sporadic Alzheimer’s in people identified as high risk through biomarker screening rather than genetic testing. Taken together, the field is moving from a single-front war on Alzheimer’s to a multi-pronged strategy that includes prevention, early intervention, and treatment of active disease. That shift — more than any single drug — is what offers the most durable reason for hope.
Conclusion
The research landscape for Alzheimer’s prevention and treatment has shifted more in the past two years than in the previous two decades. Levetiracetam’s ability to block amyloid-beta 42 production at the neuronal level, lecanemab and donanemab’s demonstrated ability to slow cognitive decline by 27 to 35 percent, and the Washington University trial’s roughly 50 percent risk reduction in genetically predisposed individuals all point in the same direction: intervening in the amyloid pathway works, and the earlier you do it, the better the outcome. For families navigating Alzheimer’s risk today, the practical takeaway is to stay informed without getting ahead of the science.
Talk to a neurologist about your personal risk profile. Pursue the lifestyle factors that have consistent evidence behind them. Watch for clinical trial opportunities, particularly if you have a family history of the disease. And take the “30 percent” headline for what it actually represents — not a single magic number, but a constellation of findings that collectively suggest we are closer to meaningful Alzheimer’s prevention than at any point in history.
Frequently Asked Questions
Is levetiracetam approved to treat or prevent Alzheimer’s disease?
No. Levetiracetam is FDA-approved only for epilepsy and seizure disorders. The Northwestern University findings are based on a correlative analysis of patient records, not a clinical trial for Alzheimer’s prevention. A prospective trial would be needed before it could be prescribed for that purpose.
What is the actual percentage by which these drugs reduce Alzheimer’s risk?
It varies by drug and study. Lecanemab slowed cognitive decline by 27 percent in its Phase 3 trial. Donanemab showed a 35 percent slowing of clinical decline and a 39 percent lower risk of disease progression. The levetiracetam study did not report a specific percentage but found patients lived several years longer after cognitive decline began. No single study reported exactly 30 percent.
How early would someone need to start taking levetiracetam for it to potentially prevent Alzheimer’s?
According to the Northwestern researchers, the drug would likely need to be started up to 20 years before cognitive decline becomes detectable. For someone who might develop symptoms at 70, that could mean beginning the medication in their 40s or 50s.
What are the side effects of lecanemab and donanemab?
Both antibody drugs carry a risk of amyloid-related imaging abnormalities, or ARIA, which can include brain swelling and microbleeds. These are typically monitored through regular MRI scans. Both drugs also require intravenous infusions at medical facilities and cost tens of thousands of dollars per year.
Can lifestyle changes reduce Alzheimer’s risk as much as these drugs?
Lifestyle interventions — including regular exercise, blood pressure management, quality sleep, and social engagement — have consistent evidence supporting their role in reducing dementia risk, though precise risk reduction percentages vary across studies. These approaches are complementary to pharmaceutical interventions, not replacements, and they are available to everyone right now at no cost.
You Might Also Like
- The Hormone Therapy Reducing Breast Cancer Risk by 50 Percent
- Why Patients Are Quitting This ADHD Drug in Record Numbers
- Tics, Tremors, and This New Drug: How It’s Changing Pediatric Neurology
For more, see Alzheimer’s Association — clinical trials.
